新辅助放疗改善T3/4N+M0直肠癌总生存:基于20300例人群研究
该研究基于SEER数据库2004–2016年20300例直肠癌患者,比较单纯手术、新辅助放疗、辅助放疗及手术加化疗对总生存的影响。结果显示T3/4N+M0患者中新辅助放疗总生存显著优于辅助放疗和手术加化疗,但在T3/4N0M0和T1/2N+M0患者中未见总生存优势。
要点
- T3/4N+M0直肠癌中新辅助放疗总生存优于辅助放疗和手术加化疗。
- T3/4N0M0和T1/2N+M0患者中新辅助放疗无总生存优势。
- 各治疗方式总生存均优于单纯手术。
核心结论
- 在局部晚期直肠癌患者中,新辅助放疗、辅助放疗和手术加化疗的总生存均优于单纯手术。
- 对于T3/4N+M0患者,新辅助放疗的总生存显著优于辅助放疗和手术加化疗。
- 对于T3/4N0M0和T1/2N+M0患者,新辅助放疗相比辅助放疗或手术加化疗未见总生存优势。
研究设计与样本
- 基于SEER数据库2004至2016年诊断的20300例直肠癌患者的人群研究。
- 采用Kaplan-Meier分析比较不同治疗模式的患者预后,Cox Hazard回归分析确定总生存的独立预测因素。
主要发现
- T3/4N0M0患者中新辅助放疗、辅助放疗和手术加化疗的总生存相似(均p>0.05;平均生存分别为115.89个月、111.97个月和117.22个月),均优于单纯手术(均p<0.001;平均生存88.96个月)。
- T1/2N+M0患者中新辅助放疗、辅助放疗和手术加化疗的总生存相似(均p>0.05;平均生存分别为121.50个月、124.25个月和121.20个月),均优于单纯手术(均p<0.001;平均生存83.81个月)。
- T3/4N+M0患者中新辅助放疗(HR=0.436;95%CI 0.396~0.478;p<0.001)的总生存显著长于辅助放疗和手术加化疗(平均生存分别为104.47个月、93.94个月和93.62个月),均优于单纯手术(均p<0.001;平均生存54.87个月)。
- 年龄>60岁、黑人种族、未婚状态、高肿瘤分级和肿瘤大小>5 cm均与不良预后相关(均p<0.05)。
临床怎么用
- T3/4N+M0直肠癌患者可优先考虑新辅助放疗以改善总生存。
- T3/4N0M0和T1/2N+M0患者中新辅助放疗与辅助放疗或手术加化疗的总生存相当。
- 年龄>60岁、黑人种族、未婚、高肿瘤分级和肿瘤>5 cm提示预后较差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant radiotherapy (RT) has been shown to improve local control; however, whether it can improve overall survival (OS) in locally advanced rectal cancer (LARC) patients remains controversial. We therefore aimed to examine the benefits of surgery alone, neoadjuvant radiotherapy (RT), adjuvant RT, and surgery plus chemotherapy in stage II (T3/4N0M0) and III (any T and N + M0) on the OS of rectal cancer patients. METHODS: Date from the Surveillance, Epidemiology, and End Results (SEER) database diagnosed between 2004 and 2016 were used. Kaplan-Meier analyses were used to compare patient prognoses across different treatment modalities. Cox hazard regression analysis were used to identify independent predictors of OS. RESULTS: For stage T3/4N0M0 patients, neoadjuvant RT, adjuvant RT, and surgery plus chemotherapy resulted in similar OS (all p > 0.05; mean survival, 115.89 months (M), 111.97 M, and 117.22 M, respectively), with better OS observed in these patients than in patients who underwent surgery alone (all p < 0.001, mean survival, 88.96 M). For stage T1/2N + M0 patients, neoadjuvant RT, adjuvant RT, and surgery plus chemotherapy resulted in similar OS (all p > 0.05; mean survival, 121.50 M, 124.25 M, and 121.20 M, respectively), with better OS observed in these patients than in patients who underwent surgery alone (all p < 0.001, mean survival 83.81 M). For stage T3/4N + M0 patients, neoadjuvant RT (HR = 0.436; 95% CI, 0.396~0.478; p < 0.001) resulted in significantly longer OS than adjuvant RT and surgery plus chemotherapy (mean survival, 104.47 M, 93.94 M, and 93.62 M, respectively), with better OS observed in these patients than in patients who underwent surgery alone (all p < 0.001, mean survival 54.87 M). Older age (> 60 years), black race, unmarried status, high tumour grade, and tumour size > 5 cm were all associated with a poor prognosis (all p < 0.05). CONCLUSIONS: Neoadjuvant RT, adjuvant RT, and surgery plus chemotherapy results in better OS than surgery alone in LARC patients. Neoadjuvant RT has the potential to be highly recommended over adjuvant RT and surgery plus chemotherapy for T3/4N + M0 patients; however, it showed no OS advantage over adjuvant RT or surgery plus chemotherapy for T3/4N0M0 and T1/2N + M0 patients.
引用
- Zhao F, Wang J, Yu H, et al. Neoadjuvant radiotherapy improves overall survival for T3/4N+M0 rectal cancer patients: a population-based study of 20300 patients. Radiat Oncol. 2020. PMID: 32103755. doi:10.1186/s13014-020-01497-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。